Literature DB >> 19855090

The IGF-I receptor can alter the matrix metalloproteinase repertoire of tumor cells through transcriptional regulation of PKC-{alpha}.

Shun Li1, Donglei Zhang, Long Yang, Julia V Burnier, Ni Wang, Rongtuan Lin, Eunice R Lee, Robert I Glazer, Pnina Brodt.   

Abstract

The IGF-I receptor (IGF-IR) was identified as a tumor progression factor, but its role in invasion and metastasis has been the subject of some controversy. Previously we reported that in murine lung carcinoma M-27 cells, overexpression of IGF-IR increased the synthesis and activation of matrix metalloproteinase (MMP)-2 via Akt/phosphatidylinositol 3-kinase signaling. In contrast, we show here that in these and other cells, IGF-IR overexpression reduced the constitutive and phorbol 12-myristate 13-acetate (PMA)-inducible expression of three protein kinase C (PKC)-regulated metalloproteinases, MMP-3, MMP-9, and MMP-13, in cultured cells as well as in vivo in sc tumors. To elucidate the underlying mechanism, we analyzed the effect of IGF-IR on PKC expression and activity using wild-type and IGF-IR-overexpressing (M-27(IGFIR)) tumor cells. Our results show that overexpression and activation of IGF-IR reduced PKC-alpha expression, PKC activity, and downstream ERK1/2 signaling, and these effects were reversed in cells expressing kinase (Y(1131,1135,1136)F) or C-terminal (Y(1250/51)F) domain mutants of IGF-IR. This reduction was due to transcriptional down-regulation of PKC-alpha as evidenced by reduced PKC-alpha mRNA expression in a phosphatidylinositol 3-kinase-dependent manner and a blockade of PKC-alpha promoter activation as revealed by a reporter gene assay. Finally, reconstitution of PKC-alpha levels could restore MMP-9 expression levels in these cells. Collectively, these results show that IGF-IR can inhibit PKC-alpha gene transcription and thereby block the synthesis of PMA-regulated MMPs, suggesting that within the same cells, IGF-IR can act as both a positive and negative regulator of MMP expression and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855090      PMCID: PMC5419122          DOI: 10.1210/me.2009-0197

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  75 in total

Review 1.  Anchoring proteins for protein kinase C: a means for isozyme selectivity.

Authors:  D Mochly-Rosen; A S Gordon
Journal:  FASEB J       Date:  1998-01       Impact factor: 5.191

2.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Authors:  P J Kaplan; S Mohan; P Cohen; B A Foster; N M Greenberg
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

3.  Stimulation of protein kinase C modulates insulin-like growth factor-1-induced akt activation in PC12 cells.

Authors:  W H Zheng; S Kar; R Quirion
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

4.  Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.

Authors:  M Tan; P Li; M Sun; G Yin; D Yu
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

5.  IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.

Authors:  Mu-Hsin Chang; Wei-Wen Kuo; Ray-Jade Chen; Ming-Chin Lu; Fuu-Jen Tsai; Wu-Hsien Kuo; Ling-Yun Chen; Wen-Jun Wu; Chih-Yang Huang; Chun-Hsien Chu
Journal:  J Mol Endocrinol       Date:  2008-05-21       Impact factor: 5.098

6.  Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.

Authors:  Donglei Zhang; Menashe Bar-Eli; Sylvain Meloche; Pnina Brodt
Journal:  J Biol Chem       Date:  2004-03-01       Impact factor: 5.157

Review 7.  Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway.

Authors:  Eddy Himpe; Ron Kooijman
Journal:  Biofactors       Date:  2009 Jan-Feb       Impact factor: 6.113

8.  Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Authors:  Borhane Annabi; Mounia Bouzeghrane; Jean-Christophe Currie; Hélène Dulude; Luc Daigneault; Seema Garde; Shafaat A Rabbani; Chandra Panchal; Jinzi J Wu; Richard Béliveau
Journal:  Anticancer Drugs       Date:  2006-04       Impact factor: 2.248

9.  Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor.

Authors:  L Long; R Rubin; R Baserga; P Brodt
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

10.  The interferon-gamma-mediated inhibition of lipoprotein lipase gene transcription in macrophages involves casein kinase 2- and phosphoinositide-3-kinase-mediated regulation of transcription factors Sp1 and Sp3.

Authors:  Sandra M Harris; Elizabeth J Harvey; Timothy R Hughes; Dipak P Ramji
Journal:  Cell Signal       Date:  2008-08-28       Impact factor: 4.315

View more
  4 in total

1.  The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor.

Authors:  Cecilia A Fernandez; Roopali Roy; Sunyoung Lee; Jiang Yang; Dipak Panigrahy; Krystyn J Van Vliet; Marsha A Moses
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

2.  IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition.

Authors:  Logan A Walsh; Sashko Damjanovski
Journal:  Cell Commun Signal       Date:  2011-05-02       Impact factor: 5.712

3.  The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis.

Authors:  E Seccareccia; M Pinard; N Wang; S Li; J Burnier; D Dankort; P Brodt
Journal:  Oncogenesis       Date:  2014-08-18       Impact factor: 7.485

4.  Cardioprotective Effect of Decorin in Type 2 Diabetes.

Authors:  Fuqiong Chen; Jinsheng Lai; Yanfang Zhu; Mengying He; Huiying Hou; Jin Wang; Chen Chen; Dao Wen Wang; Jiarong Tang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-07       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.